The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HRQoL trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, discusses the results of a prospective observational study examining the health-related quality of life (HRQoL) trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy. He highlights significant impairments in HRQoL during the first month post-infusion, followed by substantial improvements observed up to 12 months in key health domains, such as pain and fatigue. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
